Printer Friendly

Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes.

Business Editors/Health & Medical Writers

BOTHELL, Wash.--(BW HealthWire)--July 10, 2001

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the Company has been added to the Russell 2000(R) and Russell 3000(R) stock indexes.

These Russell Indexes, issued by the Frank Russell Company, are adjusted annually based on market capitalization as of May 31st. The annual rebalancing process ensures that the index provides an accurate reflection of current stock market activity and performance.

The Russell 3000, a broad market stock index, measures the performance of the 3,000 largest U.S. companies based on total market capitalization. The Russell 2000 measures the performance of the 2,000 smallest companies in the Russell 3000 index. Seattle Genetics was added to both indexes, which went into effect on July 1st and will remain effective for one year.

About Seattle Genetics

Seattle Genetics discovers and develops monoclonal antibody, or mAb, -based therapeutics to treat cancer and related diseases. The Company utilizes its mAb-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. Seattle Genetics has four mAb-based technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy. Using these technologies and its expertise in cancer, Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company also out-licenses its mAb-based technologies to strategic partners developing targeted therapies. More information about Seattle Genetics can be found at www.seattlegenetics.com.

Other than historical information set forth herein, this announcement may contain forward-looking statements that involve risks and uncertainties, including the risk that Seattle Genetics' performance over the next twelve months may not qualify it for inclusion in future Russell Indexes. Additional risks associated with Seattle Genetics' business can be found in its recent filings with the Securities and Exchange Commission, including its registration statement on Form S-1 (Registration No. 333-50266) dated March 6, 2001. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 10, 2001
Words:349
Previous Article:ADVISORY/Amazon.com Joins the All-Star Action With a Hot Air Balloon Saluting Ichiro and Sasaki.
Next Article:Fitch Upgrs Spieker Properties' Debt/Preferred Following Merger.
Topics:


Related Articles
Maxwell Technologies Added to Russell Stock Indexes.
Russell Indexes: 3Q 1999 Report; Downward Sweep: All 18 Equity Indexes Decline in Third Quarter; Large-cap Financial Services Hit Hardest With -14.8%...
Russell Posts Lists of Likely Additions/Deletions to Its U.S. Indexes; Preliminary Lists Show More Than 600 Companies Will Join the Russell 3000...
Russell Posts Final Company Membership for Stock Indexes.
Wireless Facilities Added to Russell 1000 and Russell 3000 Indexes.
Russell's 21 U.S. Equity Indexes Due for Annual Adjustment; Rebalancing Process Keeps Stock Benchmarks Tuned to Market Realities.
ProxyMed Added To Membership of Russell Indexes; Recognition For Stability, Continued Growth and Successful Performance.
Only 28 IPOs Set for Addition to Russell's Reconstituted Indexes; Annual Process Keeps Stock Benchmarks Tuned to Market Realities.
Russell 2000 Index Adds Center Financial.
Hungarian Telephone and Cable Corp. Set to Join Russell 3000 Index.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters